-
Posted by
Two Blokes Jun 29 -
Filed in
Stock
-
5 views
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioNTech signals management's ambition to revitalize growth and address long-term potential in oncology. Despite near-term 'dead money' concerns, BMY's deeply discounted valuation, while paying more than 5% in dividend yield offers an attractive margin of safety.
